Metaclipse Therapeutics (United States)

Recent papers from Metaclipse Therapeutics (United States)

1. Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC) 2253480The Journal of Immunology · 2026
2. Repurposing loratadine to induce ferroptosis and overcome multidrug resistance: preclinical evidence in KB-V-1 cellsFrontiers in Oncology · 2026
3. Virus like particle (VLP)-based delivery of SARS-CoV-2 spike RBD-GM-CSF fusion protein induces durable and protective response 2548The Journal of Immunology · 2025
4. Feasibility study of a personalized tumor membrane vesicle vaccine immunotherapy for head and neck squamous cell carcinoma (HNSCC).Journal of Clinical Oncology · 2024
5. Immunogenicity and protective efficacy of an influenza virus-like particle-based SARS-CoV-2 hybrid vaccine candidate in rhesus macaques2024
6. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged miceImmunity & Ageing · 2023
7. Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 VirusesVaccines · 2022
8. Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses2022
9. Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapyJournal for ImmunoTherapy of Cancer · 2021
10. Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer ModelsInternational Journal of Molecular Sciences · 2021
11. Novel small‐molecule LG1836 inhibits the in vivo growth of castration‐resistant prostate cancerThe Prostate · 2020
12. Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck CancerVaccines · 2020